Avid Bioservices Inc (CDMO)

[biopharm]

Now we have a few immunotherapy researchers where many years were taken and cut short, en route to some historic paradigm shifts in medical treatment they would be part of changing Big Pharma legacy ways. Along with the late Dr. Phil Thorpe and Dr. Andrew Parsa... we can include Dr. Alan Escher:

Alan P. Escher, Ph.D.

Dr. Alan Escher received his BSc magna cum laude from the University of Connecticut and PhD from Cornell University. Dr. Escher was previously Associate Professor and Associate Director of the Center for Transplant Immunology Research at the Loma Linda University School of Medicine, where he and his colleagues started to develop pro-apoptotic DNA vaccination for the treatment of type 1 diabetes. His laboratory was among the first to report the beneficial effects of DNA vaccination for type 1 diabetes in 1999. Later, his team successfully translated the technology to prevention of skin allograft rejection as proof-of-concept for application to organ transplantation. In 2009, he began his transition from the academic setting. He co-founded SEKRIS Biomedical to translate apoptotic DNA immunotherapy for treatment of inflammatory disorders. As Executive Vice President of Technology Development, he continued to strengthen the patent portfolio. While his presence will be sorely missed, Dr. Escher’s legacy will continue through continued development of his work and realization of his vision to control unwanted inflammation with the ADI technology.

http://sekrisbiomedical.com/alan-escher/

Ok, so who has been following the puzzle pieces. Peregrine Pharmaceuticals will certainly miss the late Dr. Thorpe.... but just very odd findings continue to surface: .. some very untimely passings of some big contributors to this hundred years fight to control cancer fighting drugs.... (or profits?!)

-------------------------------

SEKRIS Founders

Shahrokh Shabahang
Alan P. Escher

James D. Carlson, Pharm. D.

Dr. James Carlson co-founded PRACS Institute, Ltd. in 1983 and was President/CEO/owner from 1990 to 2006. After receiving his B.S. in Pharmacy from the University of Iowa in 1971, he went on to be the Director of Pharmacy at U.S.P.H.S. Indian Health Centers in New Mexico and Oklahoma, as well as an Instructor in Clinical Pharmacy with Southwest State University in Weatherford, OK. Upon completing his Doctor of Pharmacy at the University of Michigan and a Clinical Pharmacy Residency in Buffalo, NY, he relocated to Fargo, ND as Assistant Professor at the College of Pharmacy at North Dakota State University and Clinical Pharmacy Service Coordinator for the VA Medical Center. He later became Associate Professor at NDSU and served as their Clinical Pharmacy Services Coordinator. Dr. Carlson left the University in 1986 to focus all his energy on the development of PRACS Institute. Dr. Carlson holds current pharmacy licensure in North Dakota and Iowa and pharmacy research registration in Minnesota. Dr. Carlson is a member of numerous pharmaceutical professional organizations and has over 70 publications, including articles, abstracts, and book chapters.

http://sekrisbiomedical.com/james-carlson/

Science Advisory Board

Gilles Benichou
John J. Rossi
Leonard L. Bailey
Gilles Benichou
John J. Rossi
Daniel R. Salomon
Roland Tisch

Clinic Advisory Board

Joachim-Friedrich Kapp
Peter A. Gottlieb
Alan J. Garber
Gerald T. Nepom
Jay S. Skyler
Mark Peakman


Board of Directors I

Leonard L. Bailey
Joachim-Friedrich Kapp
Shahrokh Shabahang

---------------------------------------------

This below is from the Entertain This series of posts and one can easily scroll back and forth to see some other puzzle pieces... but c'mon... how does Gerald Finken land in the middle of so much common puzzle pieces.

Many paths are taken from here but James Carlson was the CEO of PRACs and JDC Development, LLC - and he recruited Kevin Soiseth who ended up as a QA leader for NDSU’s Center for Biopharmaceutical Research and Production in 2011 and 12, but only up till December 2012.

The shortest path to partnerships sometimes is the simplest but at one time many years ago.... some decided to complicate matters and carved a much longer path right through the center of Fargo.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90051402

I guess some do not like paradigm shifting biotechs with BOD's of 4 or less